Bio-Rad Laboratories, Inc. (NYSE:BIO) is scheduled to release its Q4 2025 earnings on February 12, 2026, after the market closes. The company is expected to report earnings of $2.57 per share and revenue of $694.64 million for the quarter. Investors and analysts can access the company’s earnings summary page for the latest updates on the call set for 5:00 PM ET on the same day.
Current Market Performance
On Tuesday, shares of Bio-Rad opened at $294.66. The company maintains a strong financial position, indicated by a quick ratio of 3.94 and a current ratio of 5.44. Its debt-to-equity ratio stands at a low 0.18. Bio-Rad’s stock has a 50-day moving average of $308.14 and a 200-day moving average of $300.66. The company has experienced a 52-week low of $211.43 and a high of $343.12. With a market capitalization of $7.95 billion and a price-to-earnings (P/E) ratio of -12.12, the stock exhibits a beta of 1.18, suggesting volatility in line with the overall market.
Analyst Insights and Ratings
Recent evaluations from equity research analysts indicate a mixed outlook for Bio-Rad. On October 30, Citigroup raised its price target from $350.00 to $375.00 while maintaining a “buy” rating. Around the same time, Wells Fargo & Company increased their price objective from $265.00 to $340.00, assigning the stock an “equal weight” rating. In contrast, Weiss Ratings reiterated a “sell (D-)” rating on December 29.
Overall, three analysts currently rate the stock as a Buy, while two give it a Hold rating and one issues a Sell rating. According to MarketBeat.com, Bio-Rad Laboratories holds an average rating of “Hold” with an average price target of $358.50.
Institutional Investor Activity
Institutional investment in Bio-Rad has seen notable activity recently. Geneos Wealth Management Inc. expanded its holdings by 115.2% in the second quarter, acquiring an additional 76 shares to reach a total of 142 shares, valued at approximately $34,000. Similarly, Quarry LP increased its position by 131.5% in the third quarter, adding 163 shares for a total of 287 shares, worth around $80,000.
CIBC Private Wealth Group LLC significantly escalated its holdings by 241.2%, purchasing an additional 234 shares for a total of 331 shares, valued at $93,000. Mercer Global Advisors Inc. ADV and WFA of San Diego LLC also acquired new positions during this period, indicating strong institutional interest, with hedge funds and institutional investors now owning 65.24% of the company’s stock.
About Bio-Rad Laboratories
Founded in 1952 by David and Alice Schwartz, Bio-Rad Laboratories is headquartered in Hercules, California. The company is a leading global provider of life science research and clinical diagnostic products, operating through two main segments: Life Science and Clinical Diagnostics. The Life Science segment offers a range of instruments, reagents, and consumables for applications in protein analysis, cell biology, and molecular biology. Meanwhile, the Clinical Diagnostics segment supplies quality control products, blood-typing reagents, and molecular diagnostic assays for various testing needs, including infectious disease screening.
As Bio-Rad prepares for its earnings announcement, stakeholders are keenly watching how the company performs in this competitive landscape.
